Cytokinetics (CYTK) FY2020 results: revenue $56 million, up 107.8% on the year
Cytokinetics Inc. (CYTK) reported revenue of $56 million for fiscal 2020, the year ended 31 December 2020, up 107.8% on the year before. Net income was -$127 million, and diluted earnings per share $-1.97. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2021.
Revenue
$56 million
+107.8% on the year
FY2013FY2020
Operating margin
-168.3%
-368.0% a year earlier
FY2013FY2020
Net income
-$127 million
FY2013FY2020
Diluted EPS
-$1.97
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
55.8
26.9
31.5
+107.8%
Research and development
97.0
86.1
89.1
+12.6%
Operating income
-93.9
-98.9
-88.9
Operating margin
-168.3%
-368.0%
-282.3%
Interest expense
16.0
6.6
3.8
+141.0%
Pre-tax income
n/a
n/a
-106
Income tax
0.0
0.0
0.0
Net income
-127
-122
-106
Net margin
-228.0%
-452.9%
-337.4%
Diluted EPS
-$1.97
-$2.11
-$1.95
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
8.9
-90.9
-101
Capital expenditure
11.1
2.6
0.9
+322.0%
Free cash flow
-2.1
-93.5
-102
Free cash flow margin
-3.8%
-348.1%
-324.1%
Cash from investing
-197
-74.7
5.1
Cash from financing
234
160
13.1
+46.5%
Depreciation and amortisation
1.8
1.3
1.2
+41.6%
Share-based compensation
17.6
10.8
9.8
+63.8%
Diluted shares, weighted
65m
n/a
n/a
Shares outstanding at period end
71m
59m
55m
+20.0%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
113
-10.9
25.9
Debt
136
129
42.4
+5.0%
Operating lease liabilities
0.4
2.2
0.8
-80.0%
Other liabilities
284
169
142
+67.9%
Total liabilities and equity
534
290
211
+84.2%
Fixed assets
13.3
4.5
3.2
+194.6%
Investments
418
231
156
+80.7%
Cash and equivalents
83.0
36.4
42.3
+127.8%
Receivables
4.4
5.2
2.2
-14.4%
Other assets
15.0
12.4
7.0
+21.6%
Total assets
534
290
211
+84.2%
10-K for the year ended 31 December 2020, filed 26 February 2021: the filing.